Locations:
Search IconSearch
December 10, 2017/Cancer/Research

Predictors of 30-day Unplanned Readmissions in Patients with Hematologic Malignancies

Disease-related, clinical and discharge-associated factors

mukherjee_650x450

Patients with hematologic malignancies (HM) are at risk of recurrent 30-day unplanned readmissions (UR), given high symptom burdens and repeated courses of chemotherapy. A team of Cleveland Clinic researchers, led by Sudipto Mukherjee, MD, PhD, MPH, recently sought to identify predictors of recurrent 30-day UR in patients with HM as a first step toward designing interventions for this group. Girish Kunapareddy, MD, MBA, a fellow at Cleveland Clinic Cancer Center, was first author on the abstract.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study included 259 30-day UR involving 157 hematologic malignancy patients treated at Cleveland Clinic between 2012 and 2015. Hematologic malignancies included in the analysis were acute leukemias, myelodysplastic syndromes and aggressive lymphomas. The tables below show disease-related, clinical and discharge-associated factors that are associated with 30-day UR and independently predictive of subsequent 30-day UR.

”We found several predictors of recurrent 30-day UR, notably gastrointestinal symptoms, prior admission for febrile neutropenia, those with relapsed refractory disease and constitutional symptoms, among others,” says Dr. Mukherjee, associate staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center. “These data shed light on potential areas that can be targeted for interventions to reduce these UR, which are a significant burden on these patients and not an optimal use of medical resources.” For instance, the subset of patients with relapsed/refractory disease may particularly benefit from a specialized program that includes individualized symptom management from a coordinated team and closer ambulatory follow-ups. As part of efforts to reduce 30-day UR, Cleveland Clinic has instituted five-day follow-up for all cancer patients discharged after hospitalization.

Photo Credit: ©Russell Lee

Advertisement

Related Articles

Hospice nurse with patient
March 10, 2026/Cancer/News & Insight
Centering End-of-Life Care Around What Matters Most

Goal-of-care discussions drive earlier hospice access

Dr. Lauren Kopicky headshot
March 4, 2026/Cancer/Podcast
Rethinking Axillary Management in Breast Cancer (Podcast)

Clinical trials and de-escalation strategies

Lobular breast cancer cells
February 26, 2026/Cancer/News & Insight
Standard of Care for Hormone-Sensitive Advanced Breast Cancer Also Effective for Lobular Subgroup

Combination therapy improves outcomes, but lobular patients still do worse overall than ductal counterparts

Person hugging in support group
February 25, 2026/Cancer/Patient Support
Treating Substance Use Disorder in Patients with Cancer

Bringing empathy and evidence-based practice to addiction medicine

Drs. Turk and Khatri headshots
February 23, 2026/Cancer/Podcast
Beyond Mammography (Podcast)

Supplemental screening for dense breasts

Dr. Elvin Zan headshot
February 17, 2026/Cancer/Podcast
Expanding Cancer Treatment with Theranostics (Podcast)

Combining advanced imaging with targeted therapy in prostate cancer and neuroendocrine tumors

Man touching lymph nodes
February 12, 2026/Cancer/News & Insight
EGFR-MET Bispecific Antibody Shows Promise for Metastatic Head & Neck Cancer

Early results show strong clinical benefit rates

Bispecific antibodies
February 10, 2026/Cancer/Blood Cancers
MajesTEC-3 Trial Outcomes May Change Course of Myeloma Treatment

The shifting role of cell therapy and steroids in the relapsed/refractory setting

Ad